Intratumoral G100 with the addition of pembrolizumab as well has been investigated in a phase I/II trial involving patients with follicular lymphoma and, when adding pembrolizumab in treatment, G100 resulted in an overall response rate of 33.3% and abscopal tumor regression in 72.2% of patients with limited toxicities, demonstrating the potential for the combined treatment of the intratumoral TLR4 agonist with other agents to produce immune-mediated reactions in follicular lymphoma [19]. Here, TLR4 is linked to neoplasm.